Molecular action of methotrexate in inflammatory diseases
about
Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patientsThe continuing challenges of leprosyAttenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocolsWegener's granulomatosis: current and upcoming therapiesDecreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory controlNew Oral Therapies for Psoriasis: A Comprehensive ReviewThe anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study.Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats.Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal.Adenosine signaling during acute and chronic disease statesAdenosine and bone metabolism.Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymesMethotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis.Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammationPharmacogenetics in the rheumatic diseasesA combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Adenosine in fibrosis.PharmGKB summary: methotrexate pathway.B-vitamin deficiency is protective against DSS-induced colitis in mice.Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK.Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats.Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosisPossible targeting of G protein coupled receptors to manipulate inflammation in vivo using synthetic and natural ligands.Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities.Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritisMethotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.Release of Periplasmic Nucleotidase Induced by Human Antimicrobial Peptide in E. coli Causes Accumulation of the Immunomodulator AdenosinePharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?Pharmacogenetic approaches to rheumatoid arthritis.Pharmacogenetics of methotrexate.Rutin attenuates intestinal toxicity induced by Methotrexate linked with anti-oxidative and anti-inflammatory effectsTwo inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism.Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy.Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy.Review article: practical management of inflammatory bowel disease patients taking immunomodulators.Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease.
P2860
Q21131938-485360CD-D041-4D02-B479-EB02981842F8Q24545809-DE40276E-6C8F-4D9E-8BD2-1A5CBA0BE192Q24793159-98C3EB2D-BB70-4A75-9396-90630FABA9DBQ24804964-78439B2B-000D-4BB8-8CF1-E69D8A021CB2Q24817102-45D9D90F-4CDF-431D-AD2F-AA07665169BEQ28071475-2E101B10-A47B-4E4C-9D5D-6B478F97FB83Q31132502-5C7194BD-50CE-4DF5-A441-37BEB10CFA7AQ33435868-72556252-DFC6-4163-A2DD-2428D024DC9CQ33713970-927D9ECC-8816-4130-A83B-B072B81B7C6AQ33747444-1F166047-B84F-4AF2-BD34-EB1C008227DAQ33940441-369A3E8F-AD83-4EF8-802D-F639DE7C409FQ34035228-9594F653-0199-4C08-8B86-090C06E91F85Q34036039-8C2A9CB8-3F9F-4789-AA13-9C2492F0FE4BQ34153004-3572AE02-599C-42B5-A50A-3D3371492D96Q34292553-7C2EEED4-0399-4125-AE18-251DE1AAB6F8Q34293811-91E09D91-94D5-451D-B385-EA42BBDD130CQ34358310-D8B568D4-FAA0-4CA1-A1D1-7ED14039826CQ34413330-9EF914A5-3292-4018-BA2E-A8DCD0CBFB72Q34559803-478CF2D4-19F9-4C73-ABE0-189A576C034FQ35085245-810AF2F1-3820-45B7-9DEF-22FE4D606AFEQ35115680-DEA95A5B-93FE-4E27-9C5C-A8267407B384Q35159629-826B3EF9-34E3-4DA5-A3D0-C8B0A97D56C9Q35190872-8CE3B436-4097-4AC7-935A-643FA2A49AF7Q35365324-DAF6D8CA-FB0E-40F4-AEEB-87411467B0EEQ35546429-63E5E440-63E0-43BA-93A0-FCF46DCF8ECAQ35553464-0C78583F-0566-479C-90B2-4B0C5E4E33A7Q35555217-AA226C2A-6B17-42B6-80B8-4A69844365B4Q35555441-DF7E1072-49E8-4512-B752-4608367B3D25Q35630047-A5EF1460-DA8D-4AFE-BD9E-010E4DA5566CQ35637808-CC83F52F-F0C0-4E53-8403-BF54A88A3DDAQ35775635-130CF7D9-79D0-425F-B53E-76D42D5B433EQ35814091-859E23B8-60E5-4A79-9ACF-11446836499EQ35834289-BE795BE2-AC01-40F4-97DC-C3223EE5B0C5Q35911142-A6C505F6-0F29-4263-99BA-2240650BFD67Q35953321-AAA54897-F346-4545-A7FC-B53B022D9D3EQ35967186-1BE1F48D-F249-4A6B-A8D5-939E497A4AD5Q36048817-6255EC13-CC71-4359-A979-556ECBBE1AC8Q36142613-F42311D6-BD82-434F-826F-C4AC91E31C34Q36166363-42F6C7D1-00E1-4897-9701-65E902E80C58Q36169364-7726592B-BC24-47E9-A832-44C787D95C6C
P2860
Molecular action of methotrexate in inflammatory diseases
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Molecular action of methotrexate in inflammatory diseases
@ast
Molecular action of methotrexate in inflammatory diseases
@en
Molecular action of methotrexate in inflammatory diseases
@en-gb
Molecular action of methotrexate in inflammatory diseases
@nl
type
label
Molecular action of methotrexate in inflammatory diseases
@ast
Molecular action of methotrexate in inflammatory diseases
@en
Molecular action of methotrexate in inflammatory diseases
@en-gb
Molecular action of methotrexate in inflammatory diseases
@nl
prefLabel
Molecular action of methotrexate in inflammatory diseases
@ast
Molecular action of methotrexate in inflammatory diseases
@en
Molecular action of methotrexate in inflammatory diseases
@en-gb
Molecular action of methotrexate in inflammatory diseases
@nl
P2860
P921
P3181
P356
P1476
Molecular action of methotrexate in inflammatory diseases
@en
P2093
Bruce N Cronstein
Edwin S L Chan
P2860
P2888
P304
P3181
P356
10.1186/AR419
P407
P577
2002-03-19T00:00:00Z
P5875
P6179
1012915794